Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.

Barnas JL, Simpson-Abelson MR, Yokota SJ, Kelleher RJ, Bankert RB.

Cancer Microenviron. 2010 Mar 31;3(1):29-47. doi: 10.1007/s12307-010-0044-5.

2.

Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.

Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E.

Clin Cancer Res. 2005 Aug 1;11(15):5566-71.

3.

Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.

Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, Liu Y, Wang T, Ma W, Huang S.

Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.

PMID:
23791878
4.

Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection.

Coutinho A, Caramalho I, Seixas E, Demengeot J.

Curr Top Microbiol Immunol. 2005;293:43-71. Review.

PMID:
15981475
5.

Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment.

Simpson-Abelson M, Bankert RB.

Expert Opin Ther Targets. 2008 Apr;12(4):477-90. doi: 10.1517/14728222.12.4.477 . Review.

PMID:
18348683
6.

Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells.

Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ Jr, Odunsi K, Bankert RB.

Cancer Immun. 2013 Jul 15;13:14. Print 2013.

7.

Signaling defects in anti-tumor T cells.

Frey AB, Monu N.

Immunol Rev. 2008 Apr;222:192-205. doi: 10.1111/j.1600-065X.2008.00606.x. Review.

8.

T cell recognition of human tumors: implications for molecular immunotherapy of cancer.

Ioannides CG, Whiteside TL.

Clin Immunol Immunopathol. 1993 Feb;66(2):91-106. Review.

PMID:
8453790
9.

Therapeutic gene modified cell based cancer vaccines.

Kozłowska A, Mackiewicz J, Mackiewicz A.

Gene. 2013 Aug 10;525(2):200-7. doi: 10.1016/j.gene.2013.03.056. Epub 2013 Apr 6. Review.

PMID:
23566846
10.

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH.

Cancer Res. 2001 Jun 15;61(12):4766-72.

11.
12.

Human tumor-infiltrating lymphocyte (TIL) cytotoxicity facilitated by anti-T-cell receptor antibody.

Schoof DD, Jung SE, Eberlein TJ.

Int J Cancer. 1989 Aug 15;44(2):219-24.

PMID:
2503456
13.

Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.

Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M.

Cancer. 1994 Aug 15;74(4):1275-82.

PMID:
7914469
14.

Targeting costimulatory pathways for tumor immunotherapy.

Ward RC, Kaufman HL.

Int Rev Immunol. 2007 May-Aug;26(3-4):161-96. Review.

PMID:
17558743
15.

[Dendritic cells and immune function in cancer].

Chaux P.

Pathol Biol (Paris). 1995 Dec;43(10):897-903. Review. French.

PMID:
8786896
16.

Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects.

Peng S, Trimble C, Alvarez RD, Huh WK, Lin Z, Monie A, Hung CF, Wu TC.

Gene Ther. 2008 Aug;15(16):1156-66. doi: 10.1038/gt.2008.53. Epub 2008 Apr 10.

17.

Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics.

Appleman LJ, Tzachanis D, Grader-Beck T, van Puijenbroek AA, Boussiotis VA.

J Mol Med (Berl). 2001;78(12):673-83. Review.

PMID:
11434720
18.

Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice.

Simpson-Abelson MR, Sonnenberg GF, Takita H, Yokota SJ, Conway TF Jr, Kelleher RJ Jr, Shultz LD, Barcos M, Bankert RB.

J Immunol. 2008 May 15;180(10):7009-18.

19.

Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.

Correia DV, d'Orey F, Cardoso BA, Lança T, Grosso AR, deBarros A, Martins LR, Barata JT, Silva-Santos B.

PLoS One. 2009 May 21;4(5):e5657. doi: 10.1371/journal.pone.0005657.

20.

Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L.

PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031. Epub 2013 Apr 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk